We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
August 01 2018
In an action relating to amlodipine besylate (Pfizer's Norvasc), Apotex is seeking relief in the Quebec Superior Court pursuant to:
Pfizer has brought a motion to dismiss Apotex's claim. On 25 April 2018 the Quebec Superior Court dismissed an application by Pfizer (part of the motion to dismiss) to dismiss the action, finding that the court has jurisdiction to adjudicate Apotex's claim under the Ontario Statute of Monopolies (Apotex Inc v Pfizer Ltd, 2018 QCCS 1765). The balance of Pfizer's motion to dismiss has been deferred to the trial in the liability phase of the proceeding.
For further information on this topic please contact Brandon Heard at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (firstname.lastname@example.org). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.